Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 271,652
  • Shares Outstanding, K 48,080
  • Annual Sales, $ 1,990 K
  • Annual Income, $ -59,980 K
  • 60-Month Beta 2.43
  • Price/Sales 98.89
  • Price/Cash Flow N/A
  • Price/Book 22.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.47
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.22 +21.80%
on 01/30/20
5.82 -11.68%
on 02/21/20
+0.62 (+13.72%)
since 01/24/20
3-Month
2.97 +73.06%
on 11/25/19
5.82 -11.68%
on 02/21/20
+1.97 (+62.15%)
since 11/22/19
52-Week
2.35 +118.72%
on 05/21/19
5.82 -11.68%
on 02/21/20
+0.98 (+23.56%)
since 02/22/19

Most Recent Stories

More News
Shares of Aerie Pharmaceut Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (AERI , OCUL , COLL , JNJ , MYL )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

AERI : 20.30 (-5.97%)
COLL : 23.75 (-0.75%)
OCUL : 5.14 (-9.03%)
Ocular Drug Delivery Technology Market Future Trends and Stunning Huge Growth by 2029 | OCULAR THERAPEUTIX and Alimera Sciences

report consisting of important parts, which present many aspects of the worldwide market with provides more accurate and meaningful information about the market status and future trends, trade matrix,...

ALIM : 6.58 (-0.45%)
AGN : 198.17 (-0.99%)
OCUL : 5.14 (-9.03%)
VRX.TO : 30.80 (-3.33%)
Uptrend Call Working As Ocular Therapeut Stock Rises 36.3% (OCUL)

SmarTrend identified an Uptrend for Ocular Therapeut (NASDAQ:OCUL) on November 29th, 2019 at $3.82. In approximately 2 months, Ocular Therapeut has returned 36.30% as of today's recent price of $5.20....

OCUL : 5.14 (-9.03%)
Ocular Therapeutix(TM) Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, will...

OCUL : 5.14 (-9.03%)
Ocular Drug Delivery Market Size and Revenue Projection To 2029 || OCULAR THERAPEUTIX, INC, Alimera Sciences

ALIM : 6.58 (-0.45%)
AGN : 198.17 (-0.99%)
NVS : 90.08 (-6.90%)
OCUL : 5.14 (-9.03%)
SNPHF : 19.3000 (-0.26%)
VRX.TO : 30.80 (-3.33%)
Watch for Ocular Therapeut to Potentially Pullback After Gaining 2.52% Yesterday

Ocular Therapeut (NASDAQ:OCUL) traded in a range yesterday that spanned from a low of $4.30 to a high of $4.55. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of...

OCUL : 5.14 (-9.03%)
Ocular Drug Delivery Market 2019 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2025

Ocular Drug Delivery Market 2019 Report offers a professional and in-depth study on the current state of the Global Ocular Drug Delivery Market along with competitive landscape, Ocular Drug Delivery Market...

ALIM : 6.58 (-0.45%)
AGN : 198.17 (-0.99%)
CLSD : 2.53 (-4.89%)
OCUL : 5.14 (-9.03%)
SNPHF : 19.3000 (-0.26%)
VRX.TO : 30.80 (-3.33%)
Shares of OCUL Up 33.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Ocular Therapeut (NASDAQ:OCUL) on November 29th, 2019 at $3.82. In approximately 2 months, Ocular Therapeut has returned 33.29% as of today's recent price of $5.09....

OCUL : 5.14 (-9.03%)
After Yesterday's Decline of 1.01%, Ocular Therapeut Offers Investors Better Value

Ocular Therapeut (NASDAQ:OCUL) traded in a range yesterday that spanned from a low of $3.83 to a high of $3.98. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $3.89...

OCUL : 5.14 (-9.03%)
Ocular Drug Delivery Technology Market Research Report 2020 - Industry Statistical Study Of The Forecast Years 2020-2029

An extensive and elaborate primary research on Global Ocular Drug Delivery Technology Market report sheds light on numerous facets such as growth factors, statistical growth, business enhancement strategies,...

ALIM : 6.58 (-0.45%)
AGN : 198.17 (-0.99%)
CLSD : 2.53 (-4.89%)
NVS : 90.08 (-6.90%)
OCUL : 5.14 (-9.03%)
PFE : 34.67 (-2.94%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade OCUL with:

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

2nd Resistance Point 5.73
1st Resistance Point 5.44
Last Price 5.14
1st Support Level 4.98
2nd Support Level 4.81

See More

52-Week High 5.82
Last Price 5.14
Fibonacci 61.8% 4.49
Fibonacci 50% 4.08
Fibonacci 38.2% 3.68
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar